Financial Performance - The company reported an undistributed profit of RMB 107,872,303.37 as of December 31, 2024[7]. - The proposed cash dividend distribution is RMB 1.00 per 10 shares, totaling RMB 3,870,857.20 for 38,708,572 shares participating in the distribution[7]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2024 was CNY 177,351,527.35, representing a year-over-year increase of 7.87% compared to CNY 164,412,273.10 in 2023[25]. - The net profit attributable to shareholders for 2024 was CNY -7,812,187.82, a significant decrease of 194.59% from CNY 8,259,296.58 in 2023[25]. - The basic earnings per share for 2024 was CNY -0.20, down 195.24% from CNY 0.21 in 2023[26]. - The cash flow from operating activities for 2024 increased by 41.85% to CNY 24,387,207.40, compared to CNY 17,191,765.24 in 2023[25]. - The company's total assets decreased by 5.72% to CNY 994,358,320.65 at the end of 2024, down from CNY 1,054,715,696.08 at the end of 2023[25]. - The company reported a net loss of CNY 19,559,897.22 after excluding non-recurring gains and losses, compared to a loss of CNY 10,298,455.81 in 2023[25]. - The company recorded non-recurring gains of CNY 11,747,709.40 in 2024, compared to CNY 18,557,752.39 in 2023[31]. Revenue and Growth - The company reported a significant increase in revenue, reaching RMB 1.2 billion, representing a year-over-year growth of 25%[24]. - User data indicates that the number of active users has grown to 500,000, an increase of 40% compared to the previous year[24]. - The company has provided guidance for the next quarter, expecting revenue to be between RMB 1.3 billion and RMB 1.5 billion, which would imply a growth rate of 8% to 25%[24]. - A recent acquisition of a biotech firm is projected to add an additional RMB 300 million in annual revenue[24]. - The revenue from testing reagents was RMB 162.16 million, up 9.94% year-on-year, while instrument revenue reached RMB 8.71 million, growing by 19.88%[37]. Research and Development - The company is investing 10% of its revenue into R&D for new diagnostic technologies, aiming to launch three new products by the end of the fiscal year[24]. - Research and development expenses accounted for 22.08% of operating revenue in 2024, a decrease of 2.94 percentage points from 25.02% in 2023[26]. - The total R&D investment for the year was approximately ¥39.17 million, a decrease of 4.79% compared to the previous year, with R&D expenses accounting for 22.08% of operating income[85]. - The company applied for 5 new invention patents and obtained 8 new patents during the reporting period, enhancing its competitive edge[40]. - The company has developed a proprietary RNA real-time fluorescence isothermal amplification (SAT) technology platform, distinguishing itself from traditional DNA and protein-based diagnostic methods[70]. Product Development and Innovation - New product launches include a state-of-the-art nucleic acid detection system, which is expected to enhance testing efficiency by 30%[24]. - The company launched a new product, the Hepatitis C virus nucleic acid detection kit, which received regulatory approval in February 2024[38]. - The company has developed a nucleic acid detection kit for Mycobacterium tuberculosis, aiding in the diagnosis and treatment of tuberculosis[50]. - The company has introduced a hepatitis B virus nucleic acid detection kit, which is crucial for assessing treatment efficacy and predicting recurrence risks[50]. - The company launched the world's first HBV RNA detection product for hepatitis B precision diagnosis, enhancing its product line in blood source products[72]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 15% market share within the next two years[24]. - The company completed the registration of multiple products in international markets, including Turkey, and is expanding its presence in Southeast Asia and the Middle East[42]. - The company aims to expand its market presence through innovative product offerings and strategic partnerships in the healthcare sector[49]. - The company is exploring global market opportunities in molecular diagnostics and leveraging digital economy trends to develop home-based diagnostic solutions[77]. - The company is actively integrating its supply chain in the in vitro diagnostic industry, reducing reliance on external suppliers while enhancing production automation[76]. Operational Efficiency - The gross margin for the latest quarter improved to 60%, up from 55% in the previous quarter[24]. - The company achieved a testing throughput increase of 50%, allowing for more samples to be processed in the same timeframe[24]. - The company plans to enhance its distribution network, aiming for a 20% increase in operational efficiency by the end of the year[24]. - The AutoSAT system is the first domestic high-throughput, fully automated RNA nucleic acid detection analysis system, capable of processing up to 200 samples in 24 hours, significantly reducing reporting time compared to conventional PCR methods[53][54]. Governance and Compliance - The company has established a governance framework consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and effective checks and balances[157]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[157]. - The independent directors and supervisors have maintained their positions without any changes in shareholding during the reporting period[163]. - The company has not engaged in any significant competitive activities with its controlling shareholders that could adversely affect its operations[157]. - The company is committed to improving internal governance and compliance to mitigate operational risks and ensure sustainable development[152]. Risks and Challenges - The company faces potential risks related to pricing pressure and slower-than-expected revenue growth due to changes in market demand and macroeconomic conditions[104]. - The company is exposed to intensified market competition, particularly in the molecular diagnostics sector, with many new entrants[109]. - The company faces risks related to new product registration, which typically takes 3-5 years and requires significant investment[106]. - There is a risk of core technical personnel turnover, which could adversely affect ongoing projects and competitive advantage[106]. - The industry is under significant regulatory scrutiny, with new policies affecting procurement and pricing strategies for diagnostic products[110].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥159,641,464.34, representing a 96.32% increase compared to ¥81,318,560.00 in the same period last year[4] - The net loss attributable to shareholders was ¥192,513,348.95, an improvement from a loss of ¥224,234,890.87 year-over-year[4] - The total operating revenue for Q1 2025 was CNY 159,641,464.34, a significant increase from CNY 81,318,560.00 in Q1 2024, representing a growth of approximately 96%[19] - The net loss for Q1 2025 was CNY 193,740,729.91, an improvement from a net loss of CNY 224,234,890.87 in Q1 2024, reflecting a reduction in losses of approximately 14%[20] - The basic and diluted earnings per share for Q1 2025 were both CNY -0.46, compared to CNY -0.54 in Q1 2024, showing an improvement in earnings per share[21] Research and Development - Research and development expenses totaled ¥210,333,356.42, a slight increase of 2.72% from ¥204,770,425.91 in the previous year[5] - The ratio of R&D expenses to operating revenue decreased to 131.75%, down from 251.81% in the previous year, indicating a significant increase in revenue[5] - Research and development expenses for Q1 2025 were CNY 210,333,356.42, slightly up from CNY 204,770,425.91 in Q1 2024, showing a year-over-year increase of about 2%[20] - The new drug application for Shuwozhe® has been accepted by the FDA with priority review designation for specific lung cancer patients[12] - The company’s new molecule GW5282 has been approved to commence Phase I clinical trials in China[13] - DZD8586's latest clinical data has been selected for oral presentation at the 2025 ASCO conference, highlighting its significance in chronic lymphocytic leukemia treatment[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,804,839,457.76, reflecting a 5.01% increase from ¥1,718,737,884.05 at the end of the previous year[5] - Total current assets reached RMB 1.02 billion as of March 31, 2025, compared to RMB 998.97 million at the end of 2024[16] - The total non-current assets were CNY 784,132,605.39, up from CNY 719,765,080.27, reflecting an increase of approximately 9%[18] - Total liabilities increased to CNY 1,781,305,350.81 from CNY 1,518,680,986.42, representing a growth of about 17%[18] - The equity attributable to shareholders decreased by 90.47% to ¥18,460,390.68 from ¥193,755,800.40 at the end of the previous year[5] - The company's total equity decreased to CNY 23,534,106.95 from CNY 200,056,897.63, indicating a decline of about 88%[18] Cash Flow - The company reported a net cash flow from operating activities of -¥131,666,959.46, slightly worse than -¥126,071,888.78 in the previous year[4] - The company's cash flow from operating activities for Q1 2025 was CNY 164,190,860.93, compared to CNY 96,462,224.00 in Q1 2024, indicating a substantial increase in cash inflow[23] - Net cash flow from operating activities was -$131.67 million, compared to -$126.07 million in the previous period, indicating a slight increase in cash outflow[24] - Cash inflow from operating activities totaled $189.48 million, up from $125.11 million, indicating a growth of about 51.5%[24] - Total cash inflow from investment activities was $732.18 million, down from $1.03 billion in the previous period, reflecting a decrease of approximately 29%[24] - Cash outflow for investment activities totaled $860.83 million, compared to $1.09 billion previously, showing a reduction of about 21%[24] - Net cash flow from financing activities was $262.62 million, an increase from $207.57 million in the prior period, representing a growth of approximately 26.5%[25] Government Support - The company received government subsidies amounting to ¥23,396,000.00, which are closely related to its normal business operations[6] Inventory and Assets - The company’s inventory decreased to RMB 37.54 million as of March 31, 2025, down from RMB 44.11 million at the end of 2024[16] - The company’s long-term assets include fixed assets valued at RMB 19.74 million and intangible assets valued at RMB 421.38 million as of March 31, 2025[16] - The company’s cash and cash equivalents amounted to RMB 252.51 million as of March 31, 2025, slightly up from RMB 250.16 million at the end of 2024[16]

Financial Performance - The company's revenue for Q1 2025 was ¥90,439,557.91, a decrease of 41.02% compared to ¥153,326,988.59 in the same period last year[3] - The net profit attributable to shareholders was -¥5,247,402.73, representing a decline of 169.22% from a profit of ¥7,581,160.86 in the previous year[3] - The basic earnings per share were -¥0.0617, down 168.60% from ¥0.0900 in the same period last year[3] - Net profit for Q1 2025 was a loss of ¥6,101,532.98, compared to a profit of ¥6,244,943.55 in Q1 2024, representing a significant decline[17] - The company reported a gross loss of ¥6,299,830.81 in Q1 2025, contrasting with a gross profit of ¥3,663,811.30 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities increased by 102.84% to ¥98,697,073.78, up from ¥48,657,809.26 year-on-year[3] - Cash inflows from operating activities in Q1 2025 totaled ¥270,982,750.63, slightly up from ¥269,162,596.56 in Q1 2024[21] - The total cash and cash equivalents at the end of the period reached $234,578,068.65, significantly higher than $96,114,372.78 at the end of the previous period[22] - The company reported a total cash outflow from operating activities of $172,285,676.85, down from $220,504,787.30, reflecting improved operational efficiency[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,232,636,747.40, reflecting a 7.56% increase from ¥2,075,682,593.71 at the end of the previous year[4] - Current assets totaled RMB 1,197,838,424.84, up from RMB 1,125,827,990.59, indicating an increase of about 6.4%[12] - The total liabilities increased to RMB 1,166,898,408.05 from RMB 1,003,842,721.38, representing a growth of approximately 16.3%[13] - The company’s equity remained stable at RMB 85,134,666.00, unchanged from the previous period[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,741[8] - The company’s major shareholder, Wands Investment, holds 28.88% of the shares, and a share transfer agreement has been signed with Ruiyuan International, which will result in a change of control[10] - The total equity attributable to shareholders of the parent company was ¥1,027,651,420.90, a slight decrease from ¥1,032,898,823.63[14] Operational Efficiency - The company faced a significant decline in revenue due to market environment factors and a focus on customer creditworthiness, leading to stricter customer selection standards[6] - The company incurred financial expenses of ¥4,169,995.96 in Q1 2025, an increase from ¥2,441,893.83 in Q1 2024[17] - The company experienced a significant increase in credit impairment losses, totaling ¥5,148,698.84 in Q1 2025, compared to ¥9,022,963.28 in Q1 2024[17] Investment Activities - Cash inflow from investment activities totaled $233,454,772.78, compared to $105,914,500.16 in the prior period, indicating a strong increase in investment returns[22] - The cash paid for investments was $223,000,000.00, compared to $68,104,069.44 in the previous period, indicating a strategic increase in capital expenditures[22] Research and Development - Research and development expenses totaled ¥4,806,981.53, a decrease of 24.98% from ¥6,407,936.09, while the R&D expense as a percentage of revenue increased to 5.32% from 4.18%[4] Accounting Standards - The company will not apply new accounting standards starting from 2025, maintaining current reporting practices[23]

Financial Performance - The company's operating revenue for Q1 2025 was ¥35,922,054.32, a decrease of 18.62% compared to ¥44,139,392.99 in the same period last year[3] - The net profit attributable to shareholders was -¥13,680,901.21, worsening from -¥7,273,734.39 year-on-year[3] - The net cash flow from operating activities was -¥29,964,460.23, compared to -¥19,583,685.98 in the previous year[3] - The basic and diluted earnings per share were both -¥0.17, compared to -¥0.09 in the same period last year[3] - Net profit for Q1 2025 was a loss of ¥13,728,189.49, compared to a loss of ¥7,273,734.39 in Q1 2024, indicating a worsening of 88.5%[18] - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by ¥6,407,200 compared to the previous year[8] - The total profit for Q1 2025 was -12,033,963.81 RMB, compared to -11,108,081.89 RMB in Q1 2024, indicating a further loss[30] Research and Development - Research and development expenses totaled ¥21,597,292.84, a slight decrease of 3.34% from ¥22,343,727.74 year-on-year[3] - R&D expenses accounted for 60.12% of operating revenue, an increase of 9.50 percentage points compared to 50.62% in the previous year[4] - Research and development expenses for Q1 2025 were ¥21,597,292.84, slightly down from ¥22,343,727.74 in Q1 2024[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,610[10] - The largest shareholder, Yang Tao, holds 18,625,000 shares, representing 23.65% of total shares[10] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three holding over 39%[10] Assets and Liabilities - The total current assets amount to 1,186,447,429.53 RMB, a decrease from 1,254,809,122.25 RMB in the previous period[13] - Total liabilities decreased from ¥174,260,365.07 in the previous period to ¥152,078,420.54 in the current period, a reduction of 12.7%[15] - Non-current assets increased to ¥203,280,184.37 from ¥163,061,924.85, reflecting a growth of 24.7%[14] - Total equity decreased from ¥1,243,610,682.03 to ¥1,237,649,193.36, a decline of 0.5%[15] - The total equity of the company was CNY 1,254,675,627.10, slightly down from CNY 1,256,728,291.64[27] Cash Flow - Cash received from sales of goods and services in Q1 2025 was ¥44,046,982.22, a decrease of 32.8% from ¥65,698,492.25 in Q1 2024[21] - Operating cash flow for Q1 2025 was -25,179,745.38 RMB, worsening from -18,779,701.93 RMB year-over-year[33] - The cash outflow for operating activities in Q1 2025 was 71,253,969.92 RMB, down from 85,991,125.90 RMB in Q1 2024, showing a reduction of 17.2%[33] - The company reported a net cash inflow from investment activities of CNY 108,728,931.56, an increase from CNY 65,172,502.65 in the previous period[22] Financial Stability - The company has no significant changes in the number of shares lent or borrowed through margin trading[12] - The company has not reported any new strategies or significant changes in operational status during the reporting period[12] - The company incurred a credit impairment loss of 530,940.08 RMB in Q1 2025, a significant increase from a gain of -89,688.07 RMB in Q1 2024[30]

Financial Performance - Operating revenue for Q1 2025 was CNY 6,700,423,651.41, an increase of 2.93% compared to CNY 6,509,426,910.25 in the same period last year[3] - Net profit attributable to shareholders decreased by 7.08% to CNY 561,678,908.50 from CNY 604,490,948.26 year-on-year[3] - Basic earnings per share decreased by 16.67% to CNY 0.05 from CNY 0.06 year-on-year[3] - Net profit for the first quarter of 2025 was CNY 652,303,752.78, a decrease of 8.5% compared to CNY 712,787,783.12 in the same period of 2024[18] - Total revenue from operating activities decreased to CNY 5,682,221,382.97 in Q1 2025, down 57.0% from CNY 13,219,785,766.72 in Q1 2024[20] - Operating revenue for Q1 2025 was CNY 372,968,089.76, a decrease of 50.16% compared to CNY 747,305,803.48 in Q1 2024[26] - Net profit for Q1 2025 was CNY 10,145,920.39, down 90.39% from CNY 105,754,373.03 in Q1 2024[27] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -3,996,015,804.00, compared to a positive CNY 2,082,321,318.72 in the previous year, indicating a significant change[3] - Operating cash flow turned negative at CNY -3,996,015,804.00 in Q1 2025, compared to a positive CNY 2,082,321,318.72 in Q1 2024[20] - The company’s cash flow from operating activities reflects a significant decrease, indicating potential challenges in revenue generation[29] - The net cash flow from operating activities was -241,921,943.84, compared to 201,714,792.86 in the previous period, indicating a significant decline[30] - Total cash inflow from investing activities was 276,334,282.36, while cash outflow was 463,918,261.96, resulting in a net cash flow of -187,583,979.60[30] - Cash inflow from financing activities was 2,000,000,000.00, with cash outflow totaling 2,014,296,944.44, leading to a net cash flow of -14,296,944.44[30] - The ending balance of cash and cash equivalents was 4,858,923,804.42, down from 5,302,768,166.35 at the beginning of the period[30] - The company reported a significant decrease in cash flow from operating activities, with total cash outflow reaching 712,612,824.37[30] Assets and Liabilities - Total assets at the end of the reporting period were CNY 116,066,949,868.92, a decrease of 1.55% from CNY 117,890,875,515.13 at the end of the previous year[4] - The total assets as of March 31, 2025, were CNY 116,066,949,868.92, compared to CNY 117,890,875,515.13 at the end of 2024[15] - The total liabilities decreased to CNY 64,943,804,942.65 from CNY 67,455,073,189.37 in the previous period[16] - Total assets amounted to CNY 43,490,383,882.03, slightly down from CNY 43,749,841,293.21 in the previous period[24] - Total liabilities decreased to CNY 9,241,810,729.21 from CNY 9,509,774,528.02[24] Research and Development - Research and development expenses totaled CNY 397,499,991.85, representing an increase of 5.64% from CNY 376,270,501.83 year-on-year[4] - The proportion of R&D expenses to operating revenue increased to 5.93% from 5.78% year-on-year[4] - Research and development expenses were CNY 379,609,678.30 in Q1 2025, slightly up from CNY 376,270,501.83 in Q1 2024[18] - Research and development expenses increased to CNY 3,030,387.35 in Q1 2025, compared to CNY 1,800.00 in Q1 2024[26] Shareholder Information - The company reported a total of 64,624 common shareholders at the end of the reporting period[8] - The largest shareholder, China Railway Communication Signal Group Co., Ltd., holds 62.46% of the shares, totaling 6,614,216,000 shares[8] Contracts and Revenue Sources - The total new external contracts signed in Q1 2025 amounted to CNY 72.13 billion, a decrease of 36.51% year-over-year[11] - The railway sector saw new contracts worth CNY 42.34 billion, a growth of 6.25% compared to the previous year[11] - The urban rail transit sector experienced a significant increase in new contracts, totaling CNY 22.42 billion, which is a 47.17% rise year-over-year[11] - The overseas business contracts decreased to CNY 3.43 billion, down 74.16% from the previous year[11]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 500,669,691.58, a decrease of 20.76% compared to CNY 631,799,944.73 in the same period last year[4] - Net profit attributable to shareholders was CNY 108,686,226.23, down 20.45% from CNY 136,618,294.85 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.2445, reflecting a decrease of 20.46% from CNY 0.3074 in the same period last year[4] - The weighted average return on equity decreased to 2.88%, down 0.87 percentage points from 3.75% year-on-year[4] - Total operating revenue for Q1 2025 was ¥500,669,691.58, a decrease of 20.77% compared to ¥631,799,944.73 in Q1 2024[16] - Net profit for Q1 2025 was ¥108,686,226.23, a decrease of 20.73% from ¥137,053,671.90 in Q1 2024[17] - Earnings per share for Q1 2025 was ¥0.2445, compared to ¥0.3074 in Q1 2024, reflecting a decline of 20.5%[17] - Other comprehensive income after tax for Q1 2025 was ¥118,341.36, down from ¥272,431.67 in Q1 2024[17] - The company reported a foreign exchange loss of ¥19,911,558.84 in Q1 2025, compared to a loss of ¥19,801,660.31 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 133,231,131.47, compared to negative CNY 11,281,135.63 in the previous year, indicating a significant decline in cash flow[4] - Cash flow from operating activities for Q1 2025 was -¥133,231,131.47, compared to -¥11,281,135.63 in Q1 2024, indicating a significant deterioration[19] - The cash flow statement indicates that the company is facing challenges in maintaining positive cash flow from its investment and financing activities[20] - The total net increase in cash and cash equivalents was -$165,933,133.65, indicating a significant decrease in liquidity[20] - The cash and cash equivalents at the end of the period amounted to $241,914,967.17, down from $407,848,100.82 at the beginning of the period[20] - The cash flow from financing activities showed a net outflow of -$172,001.00, primarily due to cash paid for other financing activities[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,840,028,347.20, an increase of 2.74% from CNY 5,684,379,927.39 at the end of the previous year[5] - The company's current assets totaled RMB 3,297,412,254.89, up from RMB 3,131,093,885.55 in the previous period, indicating a growth of approximately 5.3%[13] - The accounts receivable increased significantly to RMB 407,133,534.06 from RMB 73,287,174.93, reflecting a substantial rise in credit sales[12] - The total liabilities decreased to RMB 2,011,420,849.22 from RMB 1,964,576,997.00, showing a reduction of about 2.3%[14] - The cash and cash equivalents decreased to RMB 2,160,010,892.92 from RMB 2,237,596,169.16, a decline of approximately 3.5%[12] - The inventory level decreased to RMB 161,252,811.49 from RMB 193,879,318.94, indicating a reduction of about 16.8%[13] - The company reported a significant increase in accounts payable, rising to RMB 495,825,669.74 from RMB 400,638,062.67, which is an increase of approximately 23.7%[14] - The long-term equity investments decreased slightly to RMB 3,531,337.49 from RMB 3,763,167.47, reflecting a decline of about 6.2%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,009[9] - The top shareholder, Heilongjiang Publishing Group Co., Ltd., holds 57.62% of the shares, totaling 256,080,000 shares[9] - The company has not reported any significant changes in shareholder structure or major financing activities during the reporting period[11] Investment Activities - The net cash inflow from investment activities was $53,272,828.84, while the cash outflow totaled $85,974,831.02, resulting in a net cash flow of -$32,702,002.18[20] - The company paid $10,124,831.02 for the acquisition of fixed assets, intangible assets, and other long-term assets[20] - The cash flow from investment activities reflects a substantial outflow compared to the previous period, which was $12,864,121.88[20] - The company reported cash received from other investment activities of $1,421,232.88, contributing to the overall investment cash inflow[20] Future Outlook - The company will implement new accounting standards starting in 2025, which may impact future financial reporting[20] - The company has not reported any net profit from mergers under common control for the current and previous periods[18] - Research and development expenses for Q1 2025 were ¥381,058.35, a decrease of 73.06% from ¥1,408,416.33 in Q1 2024[16] - Total operating costs for Q1 2025 were ¥369,181,691.92, down 15.6% from ¥437,124,478.94 in Q1 2024[16]

Financial Performance - The company's operating revenue for Q1 2025 was ¥177,679,311.25, representing a 44.56% increase compared to ¥122,908,664.18 in the same period last year[4]. - The net loss attributable to shareholders was reduced to ¥27,264,802.83 from ¥48,891,400.92, marking a 44.23% decrease in losses year-over-year[4][8]. - The net cash flow from operating activities improved significantly, with a net outflow of ¥42,344,944.30 compared to ¥73,338,268.92 in the previous year[4][9]. - Total operating revenue for Q1 2025 reached ¥177,679,311.25, a 44.5% increase from ¥122,908,664.18 in Q1 2024[21]. - Net loss for Q1 2025 was ¥30,379,897.34, compared to a net loss of ¥48,891,400.92 in Q1 2024, representing a 37.8% improvement[22]. - The company's gross profit margin decreased to -17.4% in Q1 2025 from -39.7% in Q1 2024[21]. - Other comprehensive income for Q1 2025 was ¥11,519,068.59, compared to a loss of ¥31,541,717.40 in Q1 2024[22]. - Basic and diluted earnings per share improved to -¥0.07 in Q1 2025 from -¥0.12 in Q1 2024[23]. Research and Development - Research and development expenses totaled ¥58,010,145.52, accounting for 32.65% of operating revenue, down from 47.48% in the previous year[5][8]. - Research and development expenses remained stable at ¥58,010,145.52, slightly down from ¥58,357,773.06 year-over-year[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,782,611,352.08, a decrease of 1.53% from ¥1,810,336,339.19 at the end of the previous year[5]. - The company's current assets totaled RMB 1,236,497,274.41, down from RMB 1,283,293,364.86, indicating a decrease of about 3.64%[16]. - Cash and cash equivalents were reported at RMB 818,212,367.39, compared to RMB 908,999,900.84 in the previous period, representing a decline of approximately 9.93%[15]. - Total liabilities decreased to ¥229,713,693.54 from ¥241,514,182.80 year-over-year[18]. - Total equity decreased to ¥1,552,897,658.54 from ¥1,568,822,156.39 year-over-year[18]. Cash Flow - The company reported a total cash flow from operating activities of ¥105,163.00 in Q1 2025, compared to ¥5,265.49 in Q1 2024[22]. - Cash inflow from operating activities for Q1 2025 was $267.65 million, an increase of 16% compared to $230.67 million in Q1 2024[26]. - Net cash outflow from operating activities for Q1 2025 was -$42.34 million, an improvement from -$73.34 million in Q1 2024[27]. - Cash inflow from investment activities for Q1 2025 was $327.56 million, down 41% from $554.53 million in Q1 2024[27]. - Cash inflow from financing activities for Q1 2025 was $1 million, with a net cash outflow of -$1.31 million, compared to -$17.69 million in Q1 2024[27]. - The net increase in cash and cash equivalents for Q1 2025 was -$85.12 million, compared to an increase of $294.56 million in Q1 2024[28]. - The ending balance of cash and cash equivalents for Q1 2025 was $708.56 million, down from $758.09 million in Q1 2024[28]. - Cash received from sales and services in Q1 2025 was $173.78 million, significantly higher than $127.02 million in Q1 2024[26]. - Total cash outflow for operating activities in Q1 2025 was $310.00 million, slightly higher than $304.01 million in Q1 2024[27]. - Cash received from tax refunds in Q1 2025 was $11.05 million, a substantial increase from $0.11 million in Q1 2024[26]. Operational Efficiency - The company has increased its operational efficiency through cost control measures, leading to a reduction in overall expenses despite revenue growth[9]. - The weighted average return on net assets was -1.75%, an improvement from -2.74% in the previous year[5]. Market Expansion - The company expanded its product line with the introduction of new products, particularly in the intelligent visual perception business, contributing to revenue growth[8]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[14]. - The company has expanded its consolidation scope by adding a new subsidiary, Zinitix Co., which contributed to the increase in operating scale[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,246[10]. - The company's total liabilities and equity structure remains stable, with no significant changes reported in the shareholder composition[13]. - There were no significant changes in the shareholder structure or any new strategic partnerships announced during the reporting period[13].

Financial Performance - The company's operating revenue for Q1 2025 was ¥603,969,457.66, a decrease of 9.07% compared to the same period last year[4]. - Net profit attributable to shareholders increased by 122.27% to ¥5,129,765.53, driven by improved operational quality and government subsidies[4][8]. - Basic and diluted earnings per share rose by 50% to ¥0.03 per share[4][8]. - The company reported a net profit margin of approximately 0.28% for Q1 2025, down from 0.07% in Q1 2024[19]. - The net profit for Q1 2025 was CNY 1,855,610.93, an increase of 68.7% compared to CNY 1,099,310.93 in Q1 2024[20]. - The total comprehensive income for Q1 2025 was CNY 1,767,308.38, compared to CNY 1,203,726.29 in Q1 2024, reflecting a growth of 47%[21]. - Operating profit for Q1 2025 was CNY 2,392,234.71, a decrease of 18.8% from CNY 2,946,193.53 in Q1 2024[20]. Expenses and Costs - Research and development expenses totaled ¥37,871,158.33, accounting for 6.27% of operating revenue, an increase of 0.39 percentage points year-on-year[5]. - Total operating costs for Q1 2025 were RMB 601,897,479.15, down 9.05% from RMB 661,767,508.11 in Q1 2024[19]. - Operating costs included RMB 463,552,791.02 in cost of goods sold for Q1 2025, a decrease of 12.00% from RMB 526,100,925.06 in Q1 2024[19]. - The company incurred financial expenses of CNY 9,577,527.23 in Q1 2025, an increase of 35.5% from CNY 7,069,593.39 in Q1 2024[20]. - The company reported a decrease in sales expenses to CNY 45,226,581.01 in Q1 2025, down 15.5% from CNY 53,433,412.88 in Q1 2024[20]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,851,268,756.45, reflecting a slight increase of 0.05% from the end of the previous year[5]. - Current assets totaled RMB 3,084,338,957.65 as of March 31, 2025, a slight decrease from RMB 3,138,932,782.27 at the end of 2024[15]. - Non-current assets amounted to RMB 1,766,929,798.80 as of March 31, 2025, an increase from RMB 1,709,744,921.17 at the end of 2024[16]. - Total liabilities were RMB 1,977,261,780.79 as of March 31, 2025, slightly down from RMB 1,977,971,310.67 at the end of 2024[17]. - Shareholders' equity totaled RMB 2,874,006,975.66 as of March 31, 2025, compared to RMB 2,870,706,392.77 at the end of 2024[17]. Cash Flow - The net cash flow from operating activities was negative at -¥108,861,607.63, an improvement from -¥135,326,803.12 in the same period last year[4]. - The company reported a cash flow from operating activities net amount of CNY -108,861,607.63 for Q1 2025, an improvement from CNY -135,326,803.12 in Q1 2024[24]. - The company’s investment activities generated a net cash flow of CNY -77,092,006.71 in Q1 2025, an improvement from CNY -136,666,844.65 in Q1 2024[24]. - The cash and cash equivalents at the end of Q1 2025 were CNY 823,797,571.09, down from CNY 935,563,412.14 at the end of Q1 2024[25]. Strategic Focus - The company is focusing on enhancing profitability by prioritizing profit over scale, leading to a reduction in low-margin businesses[8]. - The company plans to focus on market expansion and new product development in the upcoming quarters[13]. Shareholder Information - The total number of shareholders and their respective holdings were disclosed, with the top shareholder holding 9.88% of the shares[9][11]. Return on Equity - The weighted average return on equity improved to 0.18%, up by 0.10 percentage points compared to the previous year[4]. Non-Recurring Items - Non-recurring gains and losses amounted to ¥2,849,890.74, primarily due to government subsidies and other factors[6][7].

Financial Performance - The company's operating revenue for Q1 2025 reached CNY 557.85 million, an increase of 44.08% compared to CNY 387.19 million in the same period last year[8]. - Net profit attributable to shareholders was CNY 93.70 million, up 73.80% from CNY 53.92 million year-on-year[8]. - The net profit after deducting non-recurring gains and losses was CNY 89.07 million, reflecting an 85.91% increase from CNY 47.91 million in the previous year[8]. - Basic and diluted earnings per share rose by 74.22% to CNY 0.8523[8][18]. - Operating profit for Q1 2025 was RMB 92.25 million, up 79% from RMB 51.58 million in Q1 2024[35]. - Net profit for Q1 2025 was RMB 94.44 million, compared to RMB 53.92 million in Q1 2024, representing a 75% increase[36]. - Total revenue for Q1 2025 reached RMB 557.85 million, a 44% increase from RMB 387.19 million in Q1 2024[35]. - The company reported a basic and diluted earnings per share of RMB 0.8523 for Q1 2025, up from RMB 0.4892 in Q1 2024[36]. Profitability and Margins - The gross profit margin for the period was 43.37%, an increase of 1.44 percentage points compared to the same period last year[11]. - Net profit attributable to shareholders increased by 73.80%, influenced by revenue growth, stable gross margin, and controlled expense growth[24]. - Net profit excluding non-recurring gains and losses rose by 85.91%, reflecting the operational leverage effect[24]. Research and Development - Research and development expenses totaled CNY 126.19 million, a year-on-year increase of 21.52%, representing 22.62% of operating revenue[8][11]. - Research and development expenses increased to RMB 126.19 million in Q1 2025, up from RMB 103.85 million in Q1 2024, reflecting a 21% rise[35]. Cash Flow and Assets - The company reported a net cash flow from operating activities increase due to a rise in cash received from sales and services[24]. - Cash flow from operating activities for Q1 2025 was RMB 74.97 million, a significant recovery from a negative cash flow of RMB -12.01 million in Q1 2024[38]. - Cash and cash equivalents at the end of Q1 2025 totaled RMB 945.66 million, compared to RMB 491.34 million at the end of Q1 2024, marking an increase of 92%[39]. - The company's cash and cash equivalents increased to RMB 952,942,581.35 from RMB 673,884,162.28, representing a growth of about 41.3%[31]. Employee and Organizational Growth - The number of employees increased by 27.46% to 803, primarily due to the acquisition of Shenzhen Mingzhan Information Technology Co., Ltd. and ongoing recruitment efforts[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,176[26]. - The largest shareholder, Lexin (Hong Kong) Investment Limited, holds 40.12% of the shares, totaling 45,016,142 shares[27]. Future Outlook and Strategy - Future strategies include continued investment in new products and technologies to sustain growth momentum[24]. - The company continues to explore new product development and market expansion strategies, although specific details were not disclosed in the current report[34]. - The company has maintained a focus on expanding its market influence and enhancing its ecosystem[24]. Balance Sheet Highlights - The company's total assets increased by 11.79% to CNY 2.96 billion compared to the end of the previous year[9][17]. - As of March 31, 2025, the company's total assets amounted to RMB 2,961,854,394.16, an increase from RMB 2,649,465,358.38 as of December 31, 2024, reflecting a growth of approximately 11.75%[30]. - The company's total equity reached RMB 2,278,072,266.85, up from RMB 2,179,369,220.54, marking an increase of approximately 4.5%[33]. - The total current liabilities increased to RMB 563,897,319.46 from RMB 353,139,507.75, showing a rise of about 60%[32]. - The company's short-term borrowings increased significantly to RMB 222,745,496.12 from RMB 500,333.33, reflecting a substantial rise[32]. - The company reported a decrease in inventory from RMB 485,620,281.18 to RMB 472,443,678.26, a decline of about 2.4%[31]. Other Financial Metrics - The weighted average return on equity increased by 1.41 percentage points to 4.26% due to the significant growth in net profit[8][18]. - The company generated RMB 678.38 million in cash inflows from operating activities in Q1 2025, compared to RMB 455.61 million in Q1 2024[38]. - The net cash flow from financing activities in Q1 2025 was RMB 217.66 million, a turnaround from a negative cash flow of RMB -93.12 million in Q1 2024[39].

Financial Performance - The company's operating revenue for Q1 2025 was ¥848,227,874.55, a decrease of 10.89% compared to ¥951,861,538.46 in the same period last year[4] - The net profit attributable to shareholders was ¥80,688,373.43, down 45.05% from ¥146,844,095.97 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥77,350,526.14, a decline of 46.65% compared to ¥144,998,666.40 in the previous year[4] - The basic earnings per share decreased by 46.88% to ¥0.17 from ¥0.32 in the same period last year[4] - The weighted average return on equity fell to 2.01%, a decrease of 1.59 percentage points from 3.60% year-on-year[4] - Total operating revenue for Q1 2025 was ¥848,227,874.55, a decrease of 10.9% compared to ¥951,861,538.46 in Q1 2024[20] - Net profit for Q1 2025 was ¥80,688,373.43, a decline of 45.0% from ¥146,808,313.87 in Q1 2024[21] - Basic and diluted earnings per share for Q1 2025 were both ¥0.17, compared to ¥0.32 in Q1 2024[22] - Research and development expenses for Q1 2025 were ¥22,398,874.04, a decrease of 18.7% from ¥27,596,773.46 in Q1 2024[20] - Other income for Q1 2025 was ¥13,165,301.95, down 40.2% from ¥21,976,148.81 in Q1 2024[21] - Financial expenses for Q1 2025 showed a net income of -¥7,847,928.43, compared to -¥3,237,124.47 in Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥362,308,651.83, compared to -¥208,377,703.66 in the previous year, indicating a worsening cash flow situation[4] - Cash inflow from operating activities in Q1 2025 totaled ¥1,157,832,818.68, an increase from ¥1,103,427,189.87 in Q1 2024[24] - Cash paid for purchasing goods and services in Q1 2025 was ¥942,220,218.42, down from ¥1,098,378,897.03 in Q1 2024[24] - The net cash flow from investing activities was 138,189,744.45, a significant improvement from -55,092,850.53 in the prior period[25] - The net cash flow from financing activities was -101,286,578.14, compared to -310,552,646.27 previously, showing a reduction in cash outflow from financing[27] - The total cash and cash equivalents at the end of the period amounted to 1,304,184,939.38, down from 1,620,961,502.29 at the beginning of the period[27] - Cash outflow from operating activities totaled 1,520,141,470.51, compared to 1,311,804,893.53 in the previous period, indicating increased operational costs[25] - The company received 509,260,972.27 in cash from borrowings, indicating reliance on debt financing[25] - The cash paid for debt repayment was 310,000,000.00, consistent with previous obligations[25] - The impact of exchange rate changes on cash and cash equivalents was -1,784,394.30, reflecting currency fluctuations[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,092,234,217.08, a slight decrease of 0.05% from ¥6,095,311,026.96 at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 2.12% to ¥4,048,353,811.83 from ¥3,964,206,797.47 at the end of the previous year[5] - The company's total liabilities and equity amounted to ¥6,092,234,217.08 as of the reporting date[18] - The total current liabilities decreased to CNY 1,966,928,246.20 from CNY 2,055,424,484.36, a reduction of approximately 4.3%[16] - The total non-current liabilities increased slightly to CNY 76,952,159.05 from CNY 75,679,745.13, showing a marginal rise of 1.68%[16] - The total equity of the company was CNY 4,048,353,811.83, reflecting a decrease from CNY 3,964,206,797.47, indicating a decline of approximately 2.1%[16] - The company's short-term loan increased from CNY 616,622,129.77 to CNY 824,488,909.02, marking a rise of about 33.7%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,388[10] - The company has not reported any significant changes in shareholder structure or financing activities during the reporting period[12] Inventory and Receivables - Accounts receivable rose significantly to CNY 636,070,492.90, up from CNY 425,254,310.67, indicating a year-over-year increase of about 49.5%[14] - The company's inventory decreased to CNY 652,555,974.38 from CNY 841,058,844.83, representing a decline of about 22.4%[15] - The company’s prepayments increased to CNY 12,225,822.46 from CNY 5,866,142.47, a growth of approximately 108.4%[15]